Patents by Inventor Peter C. Colosi

Peter C. Colosi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220016264
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: June 23, 2021
    Publication date: January 20, 2022
    Inventors: Alejandra E. ARBETMAN, Peter C. COLOSI, Michael A. LOCHRIE, Richard T. SUROSKY
  • Patent number: 11083800
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Genzyme Corporation
    Inventors: Alejandra E. Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Publication number: 20200390907
    Abstract: Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.
    Type: Application
    Filed: January 21, 2019
    Publication date: December 17, 2020
    Inventors: Paul Albert SIEVING, Ronald Avery BUSH, Peter C. COLOSI, Yong ZENG
  • Publication number: 20190314526
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: January 29, 2019
    Publication date: October 17, 2019
    Inventors: Alejandra E. ARBETMAN, Peter C. COLOSI, Michael A. LOCHRIE, Richard T. SUROSKY
  • Patent number: 10350306
    Abstract: Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Paul Albert Sieving, Ronald Avery Bush, Peter C. Colosi, Yong Zeng
  • Publication number: 20180280540
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: December 7, 2017
    Publication date: October 4, 2018
    Applicant: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Publication number: 20180214577
    Abstract: Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.
    Type: Application
    Filed: January 22, 2018
    Publication date: August 2, 2018
    Inventors: Paul Albert SIEVING, Ronald Avery BUSH, Peter C. COLOSI, Yong ZENG
  • Patent number: 9873893
    Abstract: Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 23, 2018
    Assignee: The United States of America as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Paul Albert Sieving, Ronald Avery Bush, Peter C. Colosi, Yong Zeng
  • Publication number: 20170232117
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: October 18, 2016
    Publication date: August 17, 2017
    Applicant: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Patent number: 9506083
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: November 29, 2016
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Publication number: 20160002666
    Abstract: Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.
    Type: Application
    Filed: February 14, 2014
    Publication date: January 7, 2016
    Inventors: Paul Albert SIEVING, Ronald Avery BUSH, Peter C. COLOSI, Yong ZENG
  • Patent number: 7485458
    Abstract: Accessory functions capable of supporting efficient recombinant AAV (rAAV) virion production in a suitable host cell are provided. The accessory functions are in the form of one or more vectors that are capable of being transferred between cells. Methods of producing rAAV virions are also provided. The methods can be practiced to produce commercially significant levels of rAAV particles without also generating significant levels of infectious helper virus or other contaminating by-products.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: February 3, 2009
    Assignee: Genzyme Corporation
    Inventor: Peter C. Colosi
  • Patent number: 7351577
    Abstract: One form of a composition has two types of recombinant adeno-associated virus. The first type encodes a portion of Factor VIII operably linked to an expression control element; and the second type encodes a different portion of Factor VIII operably linked to an expression control element. The first and second nucleotide sequences collectively encode a functional Factor VIII protein. Another form of the composition is a recombinant adeno-associated virus containing a nucleotide sequence encoding functional Factor VIII light or heavy chain operably linked to a tissue-specific promoter.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 1, 2008
    Assignee: Genzyme Corporation
    Inventors: Linda B. Couto, Peter C. Colosi, Xiaobing Qian
  • Patent number: 7259151
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: August 21, 2007
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Patent number: 6897063
    Abstract: Accessory functions capable of supporting efficient recombinant AAV (rAAV) virion production in a suitable host cell are provided. The accessory functions are in the form of one or more vectors that are capable of being transferred between cells. Methods of producing rAAV virions are also provided. The methods can be practiced to produce commercially significant levels of rAAV particles without also generating significant levels of infectious helper virus or other contaminating by-products.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: May 24, 2005
    Assignee: Avigen, Inc.
    Inventor: Peter C. Colosi
  • Publication number: 20030223971
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.
    Type: Application
    Filed: January 13, 2003
    Publication date: December 4, 2003
    Inventors: Gary J. Kurtzman, Peter C. Colosi, Jun Yoshida, Masaaki Mizuno, Hideho Okada
  • Publication number: 20030170896
    Abstract: Accessory functions capable of supporting efficient recombinant AAV (rAAV) virion production in a suitable host cell are provided. The accessory functions are in the form of one or more vectors that are capable of being transferred between cells. Methods of producing rAAV virions are also provided. The methods can be practiced to produce commercially significant levels of rAAV particles without also generating significant levels of infectious helper virus or other contaminating by-products.
    Type: Application
    Filed: June 19, 2002
    Publication date: September 11, 2003
    Applicant: Avigen, Inc.
    Inventor: Peter C. Colosi
  • Publication number: 20030099618
    Abstract: One form of a composition has two types of recombinant adeno-associated virus. The first type encodes a portion of Factor VIII operably linked to an expression control element; and the second type encodes a different portion of Factor VIII operably linked to an expression control element. The first and second nucleotide sequences collectively encode a functional Factor VIII protein. Another form of the composition is a recombinant adeno-associated virus containing a nucleotide sequence encoding functional Factor VIII light or heavy chain operably linked to a tissue-specific promoter.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 29, 2003
    Inventors: Linda B. Couto, Peter C. Colosi, Xiaobing Qian
  • Patent number: 6531456
    Abstract: The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: March 11, 2003
    Assignee: Avigen, Inc.
    Inventors: Gary J. Kurtzman, Peter C. Colosi
  • Patent number: 6482633
    Abstract: Accessory functions capable of supporting efficient recombinant AAV (rAAV) virion production in a suitable host cell are provided. The accessory functions are in the form of one or more vectors that are capable of being transferred between cells. Methods of producing rAAV virions are also provided. The methods can be practiced to produce commercially significant levels of rAAV particles without also generating significant levels of infectious helper virus or other contaminating by-products.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: November 19, 2002
    Assignee: Avigen, Inc.
    Inventor: Peter C. Colosi